作者
John C. Byrd,Jennifer R. Brown,Susan O’Brien,Jacqueline C. Barrientos,Neil E. Kay,Nishitha Reddy,Steven Coutré,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,Stephen Devereux,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Florence Cymbalista,Christopher Pocock,Patrick Thornton,Federico Caligaris‐Cappio,Tadeusz Robak,Julio Delgado,Stephen J. Schuster,Marco Montillo,Anna Schuh,Sven de Vos,Devinder Gill,Adrian Bloor,Claire Dearden,Carol Moreno,Jeffrey J. Jones,Alvina D. Chu,Maria Fardis,Jesse McGreivy,Fong Clow,Danelle F. James,Peter Hillmen
摘要
In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.
寻道图强
spark810
乐乐乐乐乐乐
tuanheqi
Henry
杳鸢
shinysparrow
VDC
nenoaowu
火火
活泼蜜蜂
iWatchTheMoon
ss25
五十一笑声
张子捷
527
Hayat
mmmm
Singularity
Priscilla
皖公网安备34019202002308
